Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
A class of diabetes drugs that include Merck & Co Inc's Januvia have been linked with severe joint pain, the U.S. Food and Drug Administration said on Friday.
The FDA said it had identified 33 cases of severe joint pain in patients taking a class of drugs known as DPP-4 inhibitors between Oct. 16, 2006, when the first one was approved, through Dec. 31, 2013.
The most frequent number of cases, 28, occurred with Januvia, known generically as sitagliptin. Five cases were reported with AstraZeneca Plc's Onglyza (saxagliptin) two with Boehringer Ingelheim's Tradjenta (linagliptin) and one with Takeda Pharmaceutical's Nesina (alogliptin).
http://www.reuters.com/article/2015/08/28/diabetes-drugs-warning-idUSL1N1131GD20150828
The FDA said it had identified 33 cases of severe joint pain in patients taking a class of drugs known as DPP-4 inhibitors between Oct. 16, 2006, when the first one was approved, through Dec. 31, 2013.
The most frequent number of cases, 28, occurred with Januvia, known generically as sitagliptin. Five cases were reported with AstraZeneca Plc's Onglyza (saxagliptin) two with Boehringer Ingelheim's Tradjenta (linagliptin) and one with Takeda Pharmaceutical's Nesina (alogliptin).
http://www.reuters.com/article/2015/08/28/diabetes-drugs-warning-idUSL1N1131GD20150828